Drug intelligence / Profile preview

ono nt-126

Development stage: Preclinical
Lead developer: Ono Pharmaceutical
Modality: Small Molecules
Administration: Unknown

Overview

ONO NT-126 is a potent and selective antagonist of the thromboxane A2 receptor (TXA2 receptor), developed as a tool compound and potential therapeutic for diseases where thromboxane A2-mediated signaling is implicated. It inhibits thromboxane A2-induced receptor binding and downstream signaling such as phosphoinositide hydrolysis, demonstrating high affinity and selectivity in human astrocytoma cells. It has been investigated preclinically for effects on bronchial hyperresponsiveness and airway inflammation, indicating potential utility in respiratory or allergic disorders[1][3][5].

Other names: ONO NT-126ONO-NT-126ONO-NT126ONO-NT 126

Targets

TYMP (Thymidine phosphorylase)

Beyond the preview

Go deeper on ono nt-126.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ono nt-126.

Explore the full profile